nitric oxide + paclitaxel + curcumin

The combination "nitric oxide + paclitaxel + curcumin" is an experimental, non-approved drug therapy under preclinical investigation, primarily for the treatment of solid tumors such as breast cancer. This combination brings together three distinctive agents with complementary antineoplastic mechanisms: - **Paclitaxel**: A widely used chemotherapy drug that stabilizes microtubules, preventing depolymerization, thus arresting cell division at the G2/M phase and inducing apoptosis in cancer cells (e.g., in triple-negative breast cancer)[3]. - **Curcumin**: A polyphenol derived from turmeric with antioxidant, anti-inflammatory, and anticancer properties. Preclinical evidence indicates curcumin can enhance the efficacy of paclitaxel by inhibiting multidrug resistance proteins (e.g., P-glycoprotein), modulating signaling pathways (NF-κB, PI3K/Akt), and increasing susceptibility of cancer cells to apoptosis[1][2]. - **Nitric oxide**: A gaseous signaling molecule with roles in vascular regulation, inflammation, and immune function. In cancer, nitric oxide can have both pro- and anti-tumor effects depending on concentration and context; in combination therapy, it may improve vascular perfusion and drug delivery, though specific preclinical data linking it explicitly with paclitaxel + curcumin is not detailed in the provided results. In preclinical studies, **paclitaxel + curcumin** combinations have shown synergistic effects in multiple cancer cell lines, improving cytotoxicity, overcoming drug resistance, and reducing metastasis compared to single agents[1][2][3]. These combinations have been formulated as nanoparticles or nanodrugs to address the poor solubility of both paclitaxel and curcumin, improving drug delivery and tumor targeting[3]. **Nitric oxide + paclitaxel + curcumin** is not described as a branded or clinically available product. The specific role of nitric oxide in this triplet combination is mentioned in the context of advanced formulation science (e.g., lipid-coated nanoparticles for co-delivery of curcumin and nitric oxide alongside chemotherapy)[7], but detailed mechanistic and clinical studies on the three-drug combination are currently lacking. No specific developers or manufacturers are identified for the three-part combination; most research describes in-house or academic preparation of such formulations for preclinical evaluation.